This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aorticvalve replacement (TAVR) System compared to surgical aorticvalve replacement (SAVR) and other TAVRvalves.
milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aorticvalve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.
The goal of the TAVR UNLOAD trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with clinical surveillance among patients with chronic systolic heartfailure and moderate aortic stenosis (stage B aortic stenosis).
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aorticvalve replacement (TAVR) in the treatment of heartfailure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
TAVR in heartfailure. ABSTRACT Patients with severe aortic stenosis (AS) may develop heartfailure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes.
Edwards Lifesciences is going all-in on structural heart and heartfailure, acquiring aorticvalve-maker JenaValve Technology and implantable heartfailure monitor company Endotronix for $1.2B and up to $445M in milestone payments.
New-onset persistent left bundle branch block (NOP-LBBB) at discharge after transcatheter aorticvalve replacement (TAVR) is frequent but its association with death and hospitalization for heartfailure (HHF) remains unclear.
Proposed approach for clinical management and therapeutic optimization in patients with heartfailure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.
The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. percentage points—in one-year bioprosthetic valve dysfunction favoring the Evolut platform. of those receiving the SAPIEN valve.
reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter AorticValve Replacement (TAVR). Without treatment, severe aorticvalve stenosis can lead to death.
ET Murphy Ballroom 4 ACC.24 24 planners note that attendees can gain insights from key clinical trials presented at ACC.24 24 and how those may impact clinical practice and patient care in this deep dive clinical trial session.
Investigators assessed if empagliflozin could lower the risk of hospitalization for heartfailure (HF) or death from cardiovascular disease (CVD). SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aorticvalve replacement (TAVR).
The diagnostic coronary angiogram identified only minimal coronary artery disease, but there was a severely calcified, ‘immobile’ aorticvalve. Aortic angiogram did not reveal aortic dissection. If you see this, you should Doppler the valve. In the cath lab, the patient’s blood pressure remained low.
Objective To compare long-term cardiovascular (CV) outcomes between men and women with aortic stenosis (AS) undergoing aorticvalve replacement (AVR) by the type of valve implant. In the TAVR cohort, men suffered a higher risk of death (HR: 1.24; 95% CI: 1.07 to 1.69, p<0.001) was observed in men.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content